Study guide

22.5 Thrombocytopenia & Thrombotic Microangiopathies

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

22.5 Thrombocytopenia & Thrombotic Microangiopathies

Key Takeaways Explain This Topic AI

Thrombotic thrombocytopenic purpura results from ADAMTS13 deficiency, presents with microangiopathic haemolysis, thrombocytopenia, fever, renal and neurological features, and requires urgent plasma exchange.

Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia because it fuels further thrombosis.

Heparin-induced thrombocytopenia causes a platelet fall of more than 50% at 5-10 days with thrombosis rather than bleeding, and requires an alternative anticoagulant such as argatroban or fondaparinux.

Last updated: September 2026

  • 3. Thrombocytopenias & Thrombotic Microangiopathies
  • Immune Thrombocytopenia (ITP)

Pathophysiology: Acquired autoimmune disorder characterized by isolated thrombocytopenia (<100 x 10^9/L) in the absence of other cytopenias or systemic illnesses (diagnosis of exclusion). Pathogenic IgG autoantibodies directed against platelet surface glycoprotein complexes (most commonly GpIIb/IIIa and GpIb-IX) opsonize platelets. Opsonized platelets undergo premature destruction via Fc-gamma receptors on splenic macrophages . In addition, autoantibodies bind to megakaryocytes in the bone marrow, inhibiting thrombopoiesis.

Bone Marrow Findings: Not routinely required in young patients with typical presentations, but if performed, shows normal or increased megakaryocytes with normal erythroid and myeloid lineages.

Management Guidelines (UK / ASH):

Platelets >30 x 10^9/L without bleeding: Conservative observation alone.

First-Line Therapy (platelets <30 x 10^9/L or active bleeding): Oral prednisolone (1 mg/kg/day) or high-dose pulsed dexamethasone (40 mg daily for 4 days) . In severe, active, life-threatening mucosal or central nervous system bleeding, or before urgent surgery, administer Intravenous Immunoglobulin (IVIG, 1 g/kg) to rapidly saturate splenic macrophage Fc receptors within 24–48 hours.

Second-Line Refractory Therapy: Thrombopoietin Receptor Agonists (TPO-RAs: romiplostim, eltrombopag) , rituximab , or laparoscopic splenectomy .

Thrombotic Thrombocytopenic Purpura (TTP)

Pathophysiology: Severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), the plasma zinc metalloprotease that cleaves ultra-large von Willebrand factor (UL-vWF) multimers into physiological smaller forms. In adults, >90% is acquired autoimmune, driven by inhibitory IgG autoantibodies against ADAMTS13 (rare congenital form is Upshaw-Schulman syndrome). Deficient ADAMTS13 activity results in persistence of hyper-reactive UL-vWF multimers, which spontaneously bind to platelet GpIb receptors under physiological shear stress, generating widespread, disseminated platelet-rich microthrombi throughout the microcirculation.

The Classical Clinical Pentad ("FAT RN"):

F = Fever (~50%);

A = Microangiopathic Haemolytic Anaemia (MAHA): Mechanical shearing of red blood cells passing through microvascular platelet thrombi produces abundant schistocytes (fragmented cells, helmet cells) on blood film (>1–2%), profound LDH elevation, unconjugated hyperbilirubinaemia, and absent haptoglobin; Direct Antiglobulin Test (DAT) is strictly negative ;

T = Thrombocytopenia: Severe consumptive thrombocytopenia (typically <20–30 x 10^9/L) causing extensive petechiae and purpura;

R = Renal Impairment: Usually mild/moderate proteinuria or microscopic haematuria (severe anuric renal failure is uncommon);

N = Neurological Deficits: Occurs in >60%; characteristically fluctuating and transient (waxing and waning confusion, fluctuating headache, expressive aphasia, visual field defects, seizures, hemiparesis, coma).

COAGULATION PROFILE PEARL: The Prothrombin Time (PT/INR), aPTT, and fibrinogen levels are COMPLETELY NORMAL in TTP ! The microvascular thrombi consist almost entirely of platelets and vWF, without significant consumption of plasma coagulation factors (in sharp contrast to DIC).

Diagnostic Confirmation: Severe ADAMTS13 activity <10% and detection of anti-ADAMTS13 IgG antibodies.

Emergency Treatment:

EMERGENT THERAPEUTIC PLASMA EXCHANGE (PEX): Must be started immediately upon clinical suspicion! PEX removes circulating anti-ADAMTS13 autoantibodies and replenishes active ADAMTS13 metalloprotease from donor plasma. Continued daily until platelet count >150 x 10^9/L for >=2 consecutive days.

High-dose systemic corticosteroids (IV methylprednisolone or oral prednisolone 1 mg/kg) and rituximab .

Caplacizumab: A bivalent humanized anti-vWF nanobody that specifically blocks the interaction between vWF A1-domains and platelet GpIb receptors, rapidly stopping further platelet consumption.

CRITICAL CONTRAINDICATION: PLATELET TRANSFUSIONS ARE STRICTLY CONTRAINDICATED IN TTP ! Administering platelets "fuels the fire" by providing additional substrate for microvascular thrombosis, precipitating acute myocardial infarction, cerebral stroke, and sudden cardiac arrest. Platelet transfusion is restricted solely to catastrophic, life-threatening intracranial haemorrhage.

Haemolytic Uraemic Syndrome (HUS)

Typical / STEC-HUS: Primarily affects children <5 years following an enteric prodrome with Shiga-toxin-producing Escherichia coli (STEC, serotype O157:H7 ) or Shigella dysenteriae . Shiga toxin binds to globotriaosylceramide (Gb3) receptors on glomerular endothelial cells, triggering endothelial apoptosis and localized microvascular thrombosis.

Clinical Triad: (1) Microangiopathic haemolytic anaemia with schistocytes; (2) Severe acute oliguric/anuric acute kidney injury (AKI) ; and (3) Consumptive thrombocytopenia. Preceded by abdominal pain and bloody diarrhoea . Coagulation tests (PT/aPTT) are normal.

Management: Supportive: Careful fluid and electrolyte management and renal replacement therapy (haemodialysis). Antibiotics and antimotility agents are contraindicated in STEC gastroenteritis because they induce bacterial lysis, increasing Shiga toxin release and heightening HUS severity.

Disseminated Intravascular Coagulation (DIC)

Pathophysiology: Systemic, uncontrolled activation of the coagulation cascade triggered by massive exposure of tissue factor or procoagulant toxins into the circulation (sepsis, severe trauma, obstetric emergencies, APML). Results in widespread microvascular fibrin deposition causing multiorgan failure, alongside simultaneous consumptive exhaustion of platelets and clotting factors and hyperfibrinolysis, precipitating severe systemic bleeding.

Laboratory Hallmarks: Prolonged PT/INR, prolonged aPTT, severe thrombocytopenia, profoundly depleted fibrinogen (<1.5 g/L), and massively elevated D-dimer / FDPs .

Heparin-Induced Thrombocytopenia (HIT Type II)

Pathophysiology: A life-threatening, immune-mediated prothrombotic drug reaction. Exposure to unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) stimulates formation of pathogenic IgG autoantibodies directed against multimolecular complexes of Platelet Factor 4 (PF4) and heparin . The Fc portions of these IgG-PF4-heparin complexes bind to Fc-gamma-RIIa receptors on adjacent platelets, inducing massive platelet activation, aggregation, and release of prothrombotic microparticles and thrombin.

Clinical Presentation: Classically occurs 5 to 10 days after starting heparin (or within 24 hours if heparin exposure occurred within the preceding 100 days). Defined by a >=50% fall in platelet count from the post-heparin peak (even if the absolute platelet count remains within the normal reference range, e.g. falling from 340 to 150 x 10^9/L).

Paradoxical Thrombosis: HIT is NOT a bleeding disorder; it is an aggressive prothrombotic state ! Up to 50% of untreated patients develop catastrophic venous thromboembolism (deep vein thrombosis, pulmonary embolism) or arterial thrombosis (limb ischaemia, stroke, myocardial infarction), known as "white clot syndrome", alongside skin necrosis at heparin injection sites.

Immediate Management Protocol:

IMMEDIATELY STOP ALL HEPARIN PRODUCTS (including LMWH, heparin line flushes, and heparin-coated catheters);

SWITCH TO A NON-HEPARIN PARENTERAL ANTICOAGULANT: Direct thrombin inhibitor ( Argatroban ) or Factor Xa inhibitor ( Fondaparinux , danaparoid);

ABSOLUTE CONTRAINDICATION - WARFARIN: Warfarin must NEVER be commenced during acute HIT ! Warfarin rapidly depletes endogenous Protein C (half-life ~6 hours) before clearing prothrombin, creating an extreme procoagulant state that precipitates microvascular thrombosis and catastrophic venous limb gangrene or skin necrosis . Warfarin may only be introduced once the platelet count has completely normalized (>=150 x 10^9/L) and must be overlapped with a non-heparin anticoagulant for >=5 days.

4. Comparative Table: TTP vs. HUS vs. DIC vs. HIT

Feature Thrombotic Thrombocytopenic Purpura (TTP) Haemolytic Uraemic Syndrome (STEC-HUS) Disseminated Intravascular Coagulation (DIC) Heparin-Induced Thrombocytopenia (HIT Type II)

Primary Pathophysiology Autoimmune deficiency of ADAMTS13 (<10%) ; UL-vWF multimers Shiga-toxin mediated glomerular endothelial injury Widespread systemic tissue factor activation; consumptive coagulopathy IgG antibodies against PF4-heparin complexes activating platelets

Typical Clinical Trigger / Context Often idiopathic; SLE, pregnancy, ticlopidine STEC O157:H7 or Shigella bloody diarrhoea prodrome Severe sepsis, major trauma, amniotic fluid embolism, APML Exposure to heparin (UFH > LMWH) 5–10 days earlier

Dominant Clinical Features Neurological deficits (fluctuating) , fever, petechiae Severe anuric AKI in young children; hypertension Widespread bleeding (venepuncture sites) + multi-organ ischaemia Paradoxical venous and arterial thrombosis (DVT, PE, stroke)

Platelet Count Severe thrombocytopenia (typically <20–30 x 10^9/L) Severe thrombocytopenia (typically <50 x 10^9/L) Severe progressive thrombocytopenia >=50% drop from baseline (often 40–100 x 10^9/L)

  • Coagulation: PT / aPTT COMPLETELY NORMAL COMPLETELY NORMAL BOTH MARKEDLY PROLONGED COMPLETELY NORMAL
  • Serum Fibrinogen Normal Normal PROFOUNDLY LOW (<1.0–1.5 g/L) Normal

Blood Film Morphology Abundant schistocytes (>1–2%); DAT negative Abundant schistocytes ; DAT negative Fragmented cells / schistocytes present Normal red cell morphology; no schistocytes

Definitive First-Line Management Emergent Plasma Exchange (PEX) + Steroids + Caplacizumab Supportive haemodialysis + strict fluid management Treat underlying cause + Cryoprecipitate, FFP, Platelets Stop all heparin ; initiate Argatroban or Fondaparinux

Critical Drug / Product Contraindications PLATELET TRANSFUSIONS ARE CONTRAINDICATED Antibiotics and antimotility agents contraindicated Unfractionated heparin contraindicated if bleeding WARFARIN IS CONTRAINDICATED in acute phase